Guyer William sold $1.9M of CORT
Guyer William (Chief Development Officer) sold 20,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $93.13 ($93.11–$93.54, $1.86M total) across 2 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
An officer sold shares in an open-market transaction under a Rule 10b5-1 plan; this is generally not a strong standalone fundamental catalyst.
Market read
Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing.
What to watch
The filing date can create short-lived headline-driven noise, but the economic signal is diluted by the pre-arranged nature and the relatively small post-sale holding size (3,985 shares remaining).
Background
The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics (CORT).
Ticker impact
Corcept Therapeutics insider sale: Chief Development Officer William Guyer sold about 20,000 shares at ~$93.13 on 2026-07-07 under a 10b5-1 plan.
Likely minimal, with any effect confined to short-term sentiment around the filing date.
The transaction is an open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretability versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it unless paired with other negative catalysts.
Key entities
- issuerCorcept Therapeutics Inc
Subject of the Form 4 insider transaction disclosure.
- insiderWilliam Guyer
Chief Development Officer who executed the sale.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan that reduces interpretive value of the sale.
